Merck, Daiichi Sankyo Add Merck's MK-6070 to Collaboration
By Colin Kellaher
Merck & Co. and Daiichi Sankyo are expanding their global collaboration to include the key drug candidate from Merck's recent purchase of Harpoon Therapeutics.
The companies on Tuesday said they plan to jointly develop and commercialize MK-6070, a T-cell engager currently being evaluated in a phase 1/2 clinical trial in certain patients with advanced cancers.
Merck and Daiichi Sankyo last year agreed to jointly develop and commercialize a trio of antibody-drug conjugates in a deal worth up to $22 billion.
The companies on Tuesday said Merck will receive an upfront cash payment of $170 million with the addition of MK-6070 to the collaboration and has also satisfied a contingent quid obligation from the original agreement.
Merck, based in Rahway, N.J., will maintain exclusive rights to MK-6070 in Japan and will be solely responsible for manufacturing and supply for the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 06, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying